REGN FY 2018 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6.7B+14.3% YoY

Gross Profit

$6.1B91.3% margin

Operating Income

$2.5B37.8% margin

Net Income

$2.4B36.4% margin

EPS (Diluted)

$21.29

Cash Flow

Operating Cash Flow

$2.2B

Free Cash Flow

$1.8B

Stock-Based Comp.

$427M

Balance Sheet

Total Assets

$11.7B

Total Liabilities

$3.0B

Stockholders' Equity

$8.8B

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6.7B	$5.9B	+14.3%
Gross Profit	$6.1B	$5.3B	+15.0%
Operating Income	$2.5B	$2.1B	+21.9%
Net Income	$2.4B	$1.2B	+104.0%